Business
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study Execution
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study\nExecution of global patient enrollment continues to progress in pivotal study of Berubicin for the treatment of GBM, one of the most aggressive forms of brain cancer\nHOUSTON, April 5, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM). With approvals now received from both swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, and Swissmedic, the Company can proceed with site initiation and patient enrollment in Switzerland. \n\n \n \n \n \n \n \n\n \n\"With the necessary regulatory approvals in Switzerland now in place, our team is diligently working to bring clinical sites online and quickly and efficiently drive patient enrollment in this potentially pivotal study. We are sincerely grateful to the Swiss Competent Authority and Ethics Committee and their positive feedback on what we continue to believe is an incredibly important clinical program. We are laser focused on advancing Berubicin to unlock its greatest potential as a possible critical treatment option for this devastating disease. As long as the unmet medical need in GBM remains, we will continue our fight to bring hope to patients and families,\" commented John Climaco, CEO of CNS Pharmaceuticals.\nProfessor Michael Weller, MD, University Hospital Zurich and National Coordinating Investigator for the potentially pivotal study, added, \"The data Berubicin has shown to-date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefit and I look forward to further exploring Berubicin's potential. I am excited to be able to participate in this important clinical trial and join forces with CNS Pharmaceuticals in their effort to provide what could be an important, and crucial, treatment option.\"\n...